Impact of Hospitalization on High-sensitivity Cardiac Troponin T Concentrations Depending on Disease Severity

Impact of Hospitalization on High-sensitivity Cardiac Troponin T Concentrations Depending on Disease Severity (Inpatient Troponin T)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04963400

Enrollment

177

Registered

2021-07-15

Start date

2021-07-14

Completion date

2024-01-17

Last updated

2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-cardiac Disease

Brief summary

We aim to examine, whether hospitalization is associated with higher high-sensitivity cardiac troponin T (hs-cTnT) serum concentrations in patients without a cardiac disease.

Detailed description

High-sensitivity cardiac troponin T (hs-cTnT) values will be obtained in hospitalized patients a) without a diagnosed or suspected cardiac disease, and b) with an acute medical condition that is not commonly associated with an increase of hs-cTnT concentrations. As a reference, a second sampling of blood for an analysis of the hs-cTnT serum concentration will be obtained in the same patients after discharge (60 days after hospitalization).

Interventions

DIAGNOSTIC_TESTAnalysis of hs-cTnT serum concentration at hospitalization

Analysis of the hs-cTnT serum concentration in the blood drawn at the day of hospitalization

DIAGNOSTIC_TESTAnalysis of hs-cTnT serum concentration after discharge

Analysis of the hs-cTnT serum concentration in the blood drawn after discharge (60 days after hospitalization)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* hospitalization due to a non-cardiac disease * age ≥ 50 years

Exclusion criteria

* diagnosed or suspected cardiac disease * acute medical conditions commonly associated with a myocardial injury (e.g. circulatory shock, sepsis, pulmonary embolism, cerebral infarction, acute renal failure)

Design outcomes

Primary

Measure	Time frame
Difference of the hs-cTnT concentration at hospitalization and after discharge	60 days

Secondary

Measure	Time frame
Difference of the hs-cTnT concentration at hospitalization and after discharge in acute medical conditions of low severity	60 days
Difference of the hs-cTnT concentration at hospitalization and after discharge in acute medical conditions of medium severity	60 days
Difference of the hs-cTnT concentration at hospitalization and after discharge in acute medical conditions of high severity	60 days
Prediction of 1-year-mortality by hs-cTnT concentration	1 year
Prediction of 1-year-hospitalization rate due to a cardiovascular disease by hs-cTnT concentration	1 year

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026